Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 8-K

PROGENICS PHARMACEUTICALS INC

Form 8-K May 24, 2004

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) May 7, 2004

PROGENICS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Registrant's telephone number, including area code (914) 789-2800

(Former name or former address, if changed since last report.)

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits

EXHIBIT NUMBER DESCRIPTION

Exhibit 99.1 Press Release dated May 7, 2004 of the Company announcing its results of operations for its first quarter and three months ended March 31, 2004 (filed herewith).

Item 12. Results of Operations and Financial Condition.

The Company furnishes its press release dated May 7, 2004, in which the Company announces, among other things, its results of operations for its first quarter and for the three months ended March 31, 2004. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROGENICS PHARMACEUTICALS, INC.

By: /s/ Philip K. Yachmetz

Philip K. Yachmetz Vice President, General Counsel and Secretary

Date: May 24, 2004